➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Colorcon
Medtronic
Moodys
Merck

Last Updated: September 28, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MIRCERA

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

All Clinical Trials for MIRCERA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00048035 A Study of Intravenous (iv) Mircera in Hemodialysis Patients With Chronic Renal Anemia Completed Hoffmann-La Roche Phase 2 2002-02-01 This study will determine the appropriate dose and frequency of administration of iv Mircera maintenance therapy in hemodialysis patients with chronic renal anemia who were previously receiving iv epoetin. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.
NCT00048048 A Study of Mircera in Anemic Patients With Chronic Kidney Disease Not Yet on Dialysis. Completed Hoffmann-La Roche Phase 2 2002-03-01 This study will evaluate the efficacy and safety of different subcutaneous starting doses and dosing frequencies of Mircera in anemic patients with chronic kidney disease not yet on dialysis. The anticipated time on study treatment is 3-12 months and the target sample size is <100 individuals.
NCT00077597 A Study of Mircera for the Treatment of Anemia in Dialysis Patients Completed Hoffmann-La Roche Phase 3 2004-02-01 This study will assess the efficacy and safety of Mircera given intravenously in the treatment of renal anemia in chronic kidney disease patients on dialysis who are not currently receiving epoetin or any other erythropoietic substance. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
NCT00077610 A Study of Intravenous Mircera for the Treatment of Anemia in Dialysis Patients Completed Hoffmann-La Roche Phase 3 2004-02-01 This study will assess the efficacy and safety of intravenous Mircera, given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving iv epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
NCT00077623 A Study of Subcutaneous Mircera for the Treatment of Anemia in Dialysis Patients. Completed Hoffmann-La Roche Phase 3 2004-03-01 This study will assess the efficacy and safety of subcutaneous (sc) Mircera given as maintenance treatment for renal anemia in chronic kidney disease patients on dialysis who were previously receiving sc epoetin. The anticipated time on study treatment is 1-2 years and the target sample size is 100-500 individuals.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for MIRCERA

Condition Name

Condition Name for MIRCERA
Intervention Trials
Anemia 56
Kidney Disease, Chronic 3
Renal Anemia of Chronic Kidney Disease 2
Chronic Renal Anemia 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for MIRCERA
Intervention Trials
Anemia 55
Renal Insufficiency, Chronic 22
Kidney Diseases 22
Chronic Disease 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for MIRCERA

Trials by Country

Trials by Country for MIRCERA
Location Trials
United States 239
Canada 39
Spain 31
Italy 28
Germany 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for MIRCERA
Location Trials
California 15
Michigan 13
New York 12
Texas 11
Ohio 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for MIRCERA

Clinical Trial Phase

Clinical Trial Phase for MIRCERA
Clinical Trial Phase Trials
Phase 4 13
Phase 3 40
Phase 2 9
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for MIRCERA
Clinical Trial Phase Trials
Completed 56
Terminated 7
Recruiting 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for MIRCERA

Sponsor Name

Sponsor Name for MIRCERA
Sponsor Trials
Hoffmann-La Roche 66
Novotech (Australia) Pty Limited 1
FibroGen 1
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for MIRCERA
Sponsor Trials
Industry 72
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Boehringer Ingelheim
Colorcon
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.